Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Multiple Myeloma 8Neoplasms, Plasma Cell 3Lymphoma, Non-Hodgkin 3Prostatic Neoplasms 2Pancreatic Neoplasms 2Smoldering Multiple Myeloma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Neoplasms by Histologic Type 1Neoplasms 1Multi-centric Castleman's Disease 1Monoclonal Gammopathy of Undetermined Significance 1Macular dystrophy, corneal type 1 1Lymphoma 1Lung Neoplasms 1Head and Neck Neoplasms 1Cytokine Release Syndrome 1Colorectal Neoplasms 1Castleman Disease 1Carcinoma, Renal Cell 1

Interventions

Sunitinib 86Sorafenib 60Everolimus 47pazopanib 46Bevacizumab 46Nivolumab 44pembrolizumab 37aldesleukin 29Interferon-alpha 26Axitinib 24temsirolimus 23cabozantinib 20Interleukin-2 19Ipilimumab 16Interferon alpha-2 15Cyclophosphamide 15fludarabine phosphate 14Gemcitabine 14Peripheral Blood Stem Cell Transplantation 11Sirolimus 10Paclitaxel 10Erlotinib Hydrochloride 10avelumab 8Radiosurgery 8Docetaxel 8Cyclosporine 8Capecitabine 8tremelimumab 7lenvatinib 7Mycophenolic Acid 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Carcinoma, Renal Cell × siltuximab × Clear all
NCT00265135 2014-07-03

A Study of CNTO 328 in Subjects With Metastatic Renal Cell Carcinoma

Centocor, Inc.

Phase 1/2 Completed
68 enrolled
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡